GlassScriptPhysician profile
Jose A Leon
NPI 1437388907
$16,540.31
in general payments reported to CMS, 2019-2025
36 companies · $3,693 in 2025
The $3,693 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $722 · 2021: $1,654 · 2022: $3,065 · 2023: $3,088 · 2024: $3,367 · 2025: $3,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,884 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,883.76 |
| Education | $263.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,616.56 | 2019-2025 | |
| Amgen INC. | $2,043.20 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,538.10 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,354.41 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,255.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,231.30 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,222.56 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $993.57 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $921.14 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $551.83 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $463.56 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $434.80 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $402.22 | 2020-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $338.03 | 2019-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $203.15 | 2022-2025 | Strensiq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $172.83 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $85.28 | 2022-2023 | Krystexxa |
| Kyowa Kirin, INC. | $66.23 | 2024-2025 | Crysvita |
| Scilex Pharmaceuticals INC. | $63.63 | 2024 | |
| Genzyme Corporation | $53.55 | 2023-2024 | |
| Genentech USA, INC. | $53.20 | 2024-2025 | Actemra, Gazyva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2024-2025 | Cyltezo, Ofev |
| Hikma Pharmaceuticals USA | $44.38 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $41.36 | 2024-2025 | Idacio |
| Ferring Pharmaceuticals INC. | $39.85 | 2025 | Euflexxa |
| Kiniksa Pharmaceuticals International, Plc | $25.33 | 2024 | Arcalyst |
| Mallinckrodt Enterprises LLC | $24.50 | 2019 | |
| Tersera Therapeutics LLC | $20.00 | 2022 | |
| Organon LLC | $18.52 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.94 | 2025 | Tremfya |
| Bioventus LLC | $15.12 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.91 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $13.13 | 2023 | Arcalyst |
| Antares Pharma, INC. | $12.09 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.